Amgen Inc.
Amgen Inc (AMGN) is a large-cap biotechnology company specialising in human therapeutics, particularly biologic medicines. With a market capitalisation around $162 billion, Amgen generates revenue from established products across oncology, nephrology, inflammation and cardiovascular care, while investing heavily in a diverse R&D pipeline of biologics and novel therapies. The company benefits from recurring revenue from long-tenured biologics, a history of steady free cash flow and a shareholder-friendly dividend policy, but faces typical sector risks: clinical trial setbacks, biosimilar competition, pricing pressure and regulatory scrutiny. Investors should watch product patent expiries, pipeline readouts and any M&A activity. This summary is for educational purposes only and not personalised investment advice; suitability depends on an investor’s goals, timeframe and risk tolerance, and returns are not guaranteed.
Why It's Moving
AMGN Stock Warning: Analysts Flag -9% Downside Amid Breakout Highs and Earnings Jitters
- Bernstein downgraded to Market Perform, warning 2026 could stall as obesity drug MariTide awaits Phase 3 data and Repatha battles Merck's new oral rival Enlicitide.
- Stock surged 13.7% in three months to hit highs, backed by ~10% revenue growth and low 15.6x forward P/E, drawing target lifts from RBC to $360 and Goldman to $415.
- Q4 earnings due Feb 10 expect $9.47B revenue (up 4.3% YoY) and $4.75 EPS despite YOY dip; Amgen's track record of beats tempers downside fears in biotech sector.
AMGN Stock Warning: Analysts Flag -9% Downside Amid Breakout Highs and Earnings Jitters
- Bernstein downgraded to Market Perform, warning 2026 could stall as obesity drug MariTide awaits Phase 3 data and Repatha battles Merck's new oral rival Enlicitide.
- Stock surged 13.7% in three months to hit highs, backed by ~10% revenue growth and low 15.6x forward P/E, drawing target lifts from RBC to $360 and Goldman to $415.
- Q4 earnings due Feb 10 expect $9.47B revenue (up 4.3% YoY) and $4.75 EPS despite YOY dip; Amgen's track record of beats tempers downside fears in biotech sector.
When is the next earnings date for Amgen Inc. (AMGN)?
Amgen's next earnings date is scheduled for April 30, 2026, following the recent Q4 2025 report released on February 3, 2026. This upcoming release will cover results for Q1 2026. Investors should monitor for the official confirmation and conference call details as the date approaches.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Amgen's stock, despite the current price being higher than its target.
Financial Health
Amgen is performing strongly with impressive profits, cash flow, and revenue generation.
Dividend
Amgen's dividend yield of 2.52% is reasonable for investors seeking regular income. If you invested $1000 you would be paid $25.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring AMGN
Hypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketProfit Sharers
These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.
Published: June 17, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Established Biologics Revenue
Amgen’s marketed biologics provide recurring sales and predictable cash flow, though revenue can be affected by patent loss and biosimilar entrants.
Pipeline & R&D Focus
A deep R&D pipeline drives long-term potential; positive trial results can re-rate the business, while failures can materially affect value.
Global Market Exposure
Amgen sells worldwide, benefiting from geographic diversification, but faces regional pricing and regulatory differences that can influence performance.
Compare Amgen with other stocks
Amgen vs Gilead Sciences
Amgen vs Gilead Sciences: Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Eli Lilly and Company
Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
